Alexion preclinical data

Alexion's lead complement inhibitor, 5G1.1-SC, was effective in blocking the complement cascade in an ex vivo model of cardiopulmonary bypass, in which human blood was run through a bypass machine.

The results, published in the Journal of Clinical Investigation, showed that the antibody fragment blocks the C5 complement protein from cleaving into C5a and C5b, thus preventing the activation interleukin-1, TNF-alpha, IL-6, and oxygen free radicals, and the activation of white blood cells. ...